Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Haematology and transfusion indexChapter sections
Purpose and principlesIndications, selection and cautionsMethod and interpretationClinical next stepsRisks, monitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook9 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Thrombocytopenia: investigation

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Time-critical presentation

Active major bleeding, new neurological or renal dysfunction with haemolysis, pregnancy hypertension with organ injury, suspected DIC, or a platelet fall with thrombosis after heparin requires immediate senior and haematology assessment. Review the blood film urgently for schistocytes and blasts. When immune TTP is plausible, send ADAMTS13 before plasma if feasible but begin the specialist treatment pathway without waiting for the result.

Purpose and principles

Confirm a genuine low platelet count, use film and clinical context to separate production, destruction, consumption and sequestration, and identify TTP, DIC, HIT and critical bleeding without delay.

A platelet count is one observation in a dynamic system. Automated analysers can undercount when platelets clump, are unusually large or adhere around leucocytes. Confirm a surprising result before labelling disease, but do not let repeat sampling delay treatment of actual bleeding or a thrombotic microangiopathy. Compare every available historical count: an abrupt fall from 300 to 100 × 10^9/L may be more mechanistically important than a stable count of 90.

Mechanisms overlap. Reduced marrow production often affects other lineages and may show macrocytosis, blasts or dysplasia. Immune destruction can be isolated with large young platelets. Consumption from sepsis, DIC, TTP, HUS or major bleeding produces systemic findings and sometimes fragments. Splenic sequestration accompanies portal hypertension and splenomegaly. Dilution follows massive transfusion or surgery. Medicines can act through immune antibodies, marrow toxicity, thrombotic microangiopathy or heparin-PF4 immune activation, so an exact exposure timeline matters.

Indications, selection and cautions

Pseudothrombocytopenia

The analyser flags clumps, the film shows platelet aggregates and an alternative-anticoagulant sample produces a more credible count without bleeding features.

Mucocutaneous bleeding

Petechiae, purpura, epistaxis, gum bleeding and menorrhagia fit platelet-type haemostasis failure more than isolated deep-muscle or joint bleeding.

Microangiopathic pattern

Schistocytes, anaemia, high LDH, low haptoglobin and organ dysfunction indicate red-cell fragmentation with platelet consumption.

TTP emergencyRed flag

Thrombocytopenia plus microangiopathic haemolysis and neurological, renal or abdominal features requires immediate plasma-exchange service contact.

Marrow warning

Blasts, dysplasia, pancytopenia, bone pain or a leucoerythroblastic film raises malignant infiltration, myelodysplasia or marrow failure.

Method and interpretation

  1. 01
    Repeat count and alternative-anticoagulant sampleFirst step
    Why
    Confirm genuine thrombocytopenia and remove EDTA-related artefact.
    Interpretation and limitations
    A corrected citrate count with visible EDTA clumps supports pseudothrombocytopenia; account for tube dilution under laboratory policy.
  2. 02
    Urgent blood film
    Why
    Identify fragments, clumps, blasts, dysplasia and platelet morphology.
    Interpretation and limitations
    Schistocytes activate a microangiopathy pathway; blasts need urgent haematology; large platelets may support peripheral destruction but are not diagnostic alone.
  3. 03
    PT, APTT, fibrinogen and D-dimer
    Why
    Assess systemic coagulation consumption and liver synthetic failure.
    Interpretation and limitations
    Prolonged times, falling fibrinogen and high fibrin breakdown fit DIC in context; TTP usually does not produce a consumptive coagulation pattern.
  4. 04
    LDH, bilirubin, haptoglobin and reticulocytes
    Why
    Detect and characterise concurrent red-cell haemolysis.
    Interpretation and limitations
    A fragmentation pattern with schistocytes directs TTP, HUS, DIC, valve and hypertensive causes; transfusion and liver disease confound individual markers.
  5. 05

Clinical next steps

01ConfirmationVerify the number without missing dangerFirst stepAn analyser reports a new low platelet count.+
  1. 1Assess active bleeding, haemodynamics, neurology, kidneys, pregnancy, sepsis, thrombosis and recent heparin before repeating a clinically unexpected count.
  2. 2Request an urgent film and repeat in citrate or another validated tube if clumping is possible, while comparing the complete historical trajectory.
  3. 3EscalationEscalate schistocytes, blasts, major bleeding or organ dysfunction immediately rather than waiting for a routine outpatient recheck.
02MechanismSort production, destruction, consumption and sequestrationTrue thrombocytopenia is confirmed and immediate resuscitation is underway if needed.+
  1. 1Review all medicines, alcohol, infection, vaccination, pregnancy, transfusion, heparin, autoimmune, liver and constitutional history and examine nodes and spleen.

Risks, monitoring and follow-up

  • Repeat platelet counts according to trajectory and diagnosis, using the same credible sampling method once pseudothrombocytopenia is resolved.
  • Monitor bleeding by site and severity, haemoglobin and haemodynamics rather than equating every count change with clinical haemostasis.
  • Trend coagulation, fibrinogen, haemolysis and organ function during sepsis, DIC, pregnancy microangiopathy or other consumptive illness.
  • After a suspected medicine cause, document withdrawal, count recovery and future avoidance in prescribing and patient-held records.
  • For chronic stable thrombocytopenia revisit alcohol, liver, spleen, infection, marrow and autoimmune features when the count pattern changes.
  • After platelet transfusion record indication, dose, increment and bleeding response and investigate repeated poor recovery rather than giving automatic extra pools.

Special situations

Trajectory carries mechanism

A rapid relative fall after heparin or sepsis can be dangerous even when the absolute count remains above conventional bleeding thresholds.

Film is a branching test

Clumps, fragments, blasts and giant platelets send the same numerical result into entirely different diagnostic and treatment pathways.

Normal coagulation narrows

TTP usually preserves routine clotting times, whereas DIC often consumes coagulation factors, although early results require serial context.

Platelets are not neutral

A component can fuel pathological thrombosis or be immediately destroyed, so diagnosis and bleeding matter more than cosmetic count correction.

Common pitfalls

  1. 01

    Diagnosing ITP before excluding platelet clumping.

  2. 02

    Waiting for ADAMTS13 before treating likely TTP.

  3. 03

    Ignoring a large relative fall after heparin.

  4. 04

    Transfusing platelets solely to normalise a number.

  5. 05

    Calling all pregnancy thrombocytopenia gestational.

  6. 06

    Missing blasts on an automated count report.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Haematology and transfusionOriginal SBA

Unexpected isolated low count

A well adult has an unexpected platelet count of 18 × 10^9/L, but the analyser flags clumping and there is no bleeding. What is the most appropriate first laboratory step?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Haematology and transfusion topics →
Sources and review status4 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Society for Haematology thrombocytopenia guidanceConfirmation, film, differential diagnosis and referral principles.
  • British Society for Haematology TMA guidelineMicroangiopathic pattern, ADAMTS13 and urgent treatment.
  • NICE blood transfusion recommendationsPlatelet thresholds, procedure support, exclusions and reassessment.
  • NICE suspected cancer recommendationsUrgent referral for abnormal counts and haematological malignancy features.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Investigation is tiered. Every patient gets clinical assessment, repeat count where needed and film. Coagulation, fibrinogen, haemolysis, renal and liver tests answer urgent mechanistic questions. Pregnancy testing and blood pressure identify obstetric microangiopathy. HIV and hepatitis testing, B12 and folate, spleen or liver imaging and marrow examination are selected from phenotype. Bone-marrow biopsy is not routine in a typical isolated ITP pattern but is appropriate with other cytopenias, abnormal film, systemic features or unexplained persistence.

Key points

  • Confirm that thrombocytopenia is real: EDTA-dependent platelet clumping, difficult sampling and platelet satellitism can produce a spuriously low automated count.
  • Repeat the count in a citrate or other validated alternative tube and inspect a blood film when clumping or an unexpected isolated result is reported.
  • First determine urgency from bleeding, physiology, neurological or renal features, pregnancy, sepsis, thrombosis and the direction and speed of count change.
  • The blood film can reveal schistocytes, blasts, dysplasia, giant platelets, malaria, clumping and a leucoerythroblastic pattern and should be reviewed early.
  • Isolated thrombocytopenia with otherwise normal film and no systemic illness suggests ITP or a drug effect after HIV, hepatitis and other secondary causes are considered.
  • Anaemia with schistocytes, raised LDH and low haptoglobin indicates microangiopathic haemolysis and activates TTP, HUS, DIC, malignant hypertension or pregnancy pathways.
  • Prolonged PT and APTT, low fibrinogen and high D-dimer support consumptive DIC in the right clinical setting but normal early coagulation does not exclude evolution.
  • A fall beginning five to ten days after heparin with new thrombosis is assessed using the 4Ts score before PF4 laboratory testing and alternative anticoagulation.
Renal, liver and infection profile
Why
Find organ injury, sequestration and systemic triggers.
Interpretation and limitations
Acute kidney injury changes TMA probability; liver disease with spleen enlargement supports sequestration; cultures and sepsis assessment are clinically directed.
  • 06
    Pregnancy test, blood pressure and obstetric tests
    Why
    Identify gestational thrombocytopenia, pre-eclampsia, HELLP and pregnancy-associated TMA.
    Interpretation and limitations
    Hypertension, proteinuria, haemolysis or liver injury requires immediate maternity coordination; gestational thrombocytopenia is mild and a diagnosis of context.
  • 07
    HIV, hepatitis B and C testing
    Why
    Identify treatable secondary immune thrombocytopenia and infection context.
    Interpretation and limitations
    Obtain consent and interpret with exposure and liver disease; a positive result changes treatment and transmission counselling.
  • 08
    Bone-marrow examination
    Why
    Investigate unexplained production failure or abnormal morphology.
    Interpretation and limitations
    Use when other lines, film, age-dependent features or treatment response raise a marrow disorder; typical isolated ITP does not routinely require it.
  • 2Use other lineages and film plus coagulation, haemolysis, renal and liver tests to identify systemic consumption or marrow failure.
  • 3Order targeted viral, nutritional, immune, imaging or marrow studies from that pattern and avoid indiscriminate panels that delay the urgent diagnosis.
    • 03Treatment interfaceLink platelet support to mechanismBleeding or a procedure prompts consideration of platelet transfusion.+
    1. 1Define bleeding site, severity, procedure and likely mechanism and discuss thresholds through current NICE and local transfusion guidance.
    2. 2Avoid prophylactic platelet transfusion in immune destruction or TMA solely to correct the count, especially in TTP and HIT without life-threatening bleeding.
    3. 3Treat the cause, reassess clinically after any component and investigate poor increments for consumption, fever, splenomegaly or alloimmunisation.
    Liver disease and splenomegaly cause sequestration, while alcohol, medicines, B12 or folate deficiency, marrow failure and malignancy reduce platelet production.
  • Do not transfuse platelets simply because the count is low; bleeding, procedure, mechanism and diagnosis determine benefit, and platelets can be harmful in TTP or HIT.